Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial
Bibliographic Data
| ID | 9260865 |
|---|---|
| Authors | Luiz Antônio Bastos Camacho (0000-0003-4656-1914, Fiocruz, Brasil), Savitri Gomes de Aguiar (Fiocruz, Brasil), Marcos Da Silva Freire (0000-0002-4723-8994, Fiocruz, Brasil), Maria Da Luz Fernandes Leal (0000-0002-8886-8116, Fiocruz, Brasil), Jussara Pereira do Nascimento (Fiocruz, Brasil), Takumi Iguchi (Fiocruz, Brasil), José Azevedo Lozana (Fiocruz, Brasil), Roberto Henrique Guedes Farias (Instituto de Biologia do Exército), Roberto Farias (Instituto de Biologia do Exército) |
| Year | 2005 |
| Volume | 39 |
| Issue | 3 |
| Pages | 413-420 |
| Publication date | 2005-06-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Revista de Saúde Pública (JOURNAL) |
| Journal identifiers | ISSN: 0034-8910 • E-ISSN: 0034-8910 |
| Publisher | FapUNIFESP (SciELO) (PUBLISHER) |
| DOI | 10.1590/s0034-89102005000300012 |
| PMID | 15997317 |
| OpenAlex | W2120524325 |
| SCIELO_PID | S0034-89102005000300012 |
| Language | EN |
| Citations received | 2 |
| References cited | 18 |
OBJECTIVE: To compare the reactogenicity of three yellow fever (YF) vaccines from WHO-17D and Brazilian 17DD substrains (different seed-lots) and placebo. METHODS: The study involved 1,087 adults eligible for YF vaccine in Rio de Janeiro, Brazil. Vaccines produced by Bio-Manguinhos, Fiocruz (Rio de Janeiro, Brazil) were administered ("day 0") following standardized procedures adapted to allow blinding and blocked randomization of participants to coded vaccine types. Adverse events after immunization were ascertained in an interview and in diary forms filled in by each participant. Liver enzymes were measured on days 0, 4-20 and 30 of the study. Viremia levels were measured on days 4 to 20 of follow-up. The immune response was verified through serologic tests. RESULTS: Participants were mostly young males. The seroconversion rate was above 98% among those seronegative before immunization. Compared to placebo, the excess risk of any local adverse events ranged from 0.9% to 2.5%, whereas for any systemic adverse events it ranged from 3.5% to 7.4% across vaccine groups. The excess risk of events leading to search for medical care or to interruption of work activities ranged from 2% to 4.5%. Viremia was detected in 3%-6% of vaccinees up to 10 days after vaccination. Variations in liver enzyme levels after vaccination were similar in placebo and vaccine recipients. CONCLUSIONS: The frequency of adverse events post-immunization against YF, accounting for the background occurrence of nonspecific signs and symptoms, was shown for the first time to be similar for vaccines from 17D and 17DD substrains. The data also provided evidence against viscerotropism of vaccine virus
Adverse effect · Alternative medicine · Antibody · Immune system · Immunization · Placebo · Randomized controlled trial · Reactogenicity · Seroconversion · Serology · Vaccination · Virus · Yellow fever · Yellow fever vaccine · Immunology · Internal Medicine · Malaria Research and Control · Medicine · Mosquito-borne diseases and control · Viral Infections and Outbreaks Research
| Unique citing works | 2 |
|---|---|
| Citations per year | 0,13 |
| Citation span | 2011 - 2017 (7) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 2 |